5Vote!
Business Wire (Free subscription) | 10/05/2009
LOS ANGELES--(BUSINESS WIRE)--Audit Integrity, an independent financial research and risk modeling firm, announced today that it has revised and upgraded Mylan Inc’s bankruptcy probability ranking. Due to a stock pricing error made by data provider Thomson Reuters, Mylan was erroneously placed among the companies most likely to go bankrupt over the next twelve months. Audit Integrity’s...
3Vote!
The Pittsburgh Business Times (Free subscription) | 08/13/2009
Federal authorities found no problems at Mylan Inc’s Morgantown W.Va. plant during an inspection last month, Food and Drug Administration spokeswoman Judy Leon said Thursday.
3Vote!
State Journal Featured Content (Free subscription) | 08/13/2009
The final report found no deficiencies.
3Vote!
Medical News Today (Free subscription) | 08/11/2009
Mylan Inc. (Nasdaq: MYL) announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Sumatriptan Succinate Tablets, 25 mg (base), 50 mg (base) and 100 mg (base). This product is manufactured in Mylan's Morgantown, W.Va. facility. Mylan Chairman and CEO Robert J.
5Vote!
Red Orbit (Free subscription) | 08/07/2009
An arrangement between former President Bill Clinton's foundation and two drug corporations will decrease prices on medicines for patients with drug-defiant HIV in developing countries.One contract, with Mylan Inc., drops the yearly cost of four antiretroviral drugs that are a second kind of treatment when patients build up a resistance to the drugs that are initially used.The other arrangement, with...
3Vote!
euronews24 (Free subscription) | 08/06/2009
NEW YORK - Former President Bill Clinton has struck an agreement with two drug companies to provide cheaper, better HIV treatments to patients in poor nations. The deal involves antiretroviral medications made by Pfizer Inc. and Mylan Inc. Clinton s ...
5Vote!
San Fransisco Chronicle (Free subscription) | 08/06/2009
Former President Bill Clinton has struck an agreement with two drug companies to provide cheaper, better HIV treatments to patients in poor nations. The deal involves antiretroviral medications made by Pfizer Inc. and Mylan Inc. Clinton says the arrangement... Sponsored Topics: Bill Clinton - HIV - Antiretroviral drug - United States - Health
2Vote!
Daily Advance - Business (Free subscription) | 08/03/2009
MORRISTOWN, N.J. — Watson Pharmaceuticals Inc. said Monday it received approval for a generic ...
6Vote!
San Fransisco Chronicle (Free subscription) | 08/03/2009
Watson Pharmaceuticals Inc. said Monday it received approval for a generic version of the high blood pressure and angina drug Toprol XL, and plans to begin shipping the product immediately. Watson said the Food and Drug Administration approval 25 mg and 50 mg... Sponsored Topics: US Food and Drug Administration - Food and Drug Administration - Hypertension - Watson Pharmaceuticals - United States
3Vote!
Hindu (Free subscription) | 08/03/2009
TOKYO: Japanese drug major Daiichi Sankyo said on Monday a U.S. Court has ruled in its favour in a patent litigation related to the anti-hypertensive drug, Benicar, against Mylan Inc and its Indian subsidiary, Matrix ...
5Vote!
Market Watch (Free subscription) | 07/30/2009
BOSTON (MarketWatch) -- Mylan Inc. led drug stocks into positive territory as shares of the generic drugmaker gained on a positive second-quarter earnings report. The NYSE Arca Pharmaceutical Index climbed 0.8% to 281.75 and the NYSE Arca Biotechnology Index edged up 0.4% to 887.82. The Dow Jones Industrial Average advanced 70 points to 9,137. Shares of Mylan were up 4% at $13.40. Market Pulse Stories...
5Vote!
The Pittsburgh Business Times (Free subscription) | 07/30/2009
Generic drug giant Mylan Inc. on Thursday reported net income of $58 million or 19 cents per share, on revenue of $1.25 billion, for the quarter ended June 30.
4Vote!
Market Watch (Free subscription) | 07/30/2009
LONDON (MarketWatch) -- Mylan Inc. swung to a second quarter profit of 19 cents a share vs. a loss of 5 cents a share a year earlier. The company raised its full-year adjusted diluted earnings guidance to a range of $1.13 to $1.20 a share. Adjusted diluted earnings, which exclude one-time items, rose to 32 cents a share in the second quarter. Market Pulse Stories are Rapid-fire, short news bursts...
5Vote!
The Pittsburgh Business Times (Free subscription) | 07/29/2009
Heather Bresch has been promoted to president of generic drug giant Mylan Inc. and Rajiv Malik was named to fill Bresch’s previous role as chief operating officer, the Canonsburg-based company announced Wednesday. (MYL)
4Vote!
Market Watch (Free subscription) | 07/29/2009
LONDON (MarketWatch) -- Watson Pharmaceuticals Inc. said Wednesday that its second-quarter net profit fell 12% to $53 million, or 46 cents a share, from $60.3 million, or 53 cents a share, a year earlier, as the group also raised its 2009 outlook. Watson said net revenue in the quarter rose 8.8% to $677.8 million and adjusted earnings were 61 cents a share. Analysts polled by FactSet had been expecting...
Videos